Evidence map›Paper›PMID 35214131›Full record

ArticlePharmaceutics2022

Effects of Ultramicronized

Laura Micheli, Elena Lucarini, Alessandra Toti, Valentina Ferrara, Clara Ciampi, Carmen Parisio, Gianluca Bartolucci, Lorenzo Di Cesare Mannelli, Carla Ghelardini

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Opioid Use and Gut Dysbiosis in Cancer Pain Patients.International journal of molecular sciences · 2024
    Review
  5. UltramicronizedCurrent neuropharmacology · 2024
    Article
  6. UltramicronizedBiomolecules · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Laura MicheliDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0001-8834-5801
Elena LucariniDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0002-3459-2660
Alessandra TotiDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0002-8435-6017
Valentina FerraraDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.
Clara CiampiDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.
Carmen ParisioDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0003-0746-0774
Gianluca BartolucciDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmaceutical and Nutraceutical Sciences Section, University of Florence, 50019 Florence, Italy.ORCID 0000-0002-5631-8769
Lorenzo Di Cesare MannelliDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0001-8374-4432
Carla GhelardiniDepartment of Neuroscience, Psychology, Drug Research and Child Health-Neurofarba-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.
University of Florence · IT

Funding

Ministry of Education, Universities and Research not availableUniversity of Florence not available
6 · The paper itself

Abstract

Chronic pain management requires increasing doses of opioids, the milestone of painkillers, which may result in the onset of tolerance with exacerbated side effects. Maintaining stable analgesia with low doses of opioids is thus imperative.

Indexed as

astrocyteopioidoxycodonepain therapyPEAtolerancetramadol

Identifiers

PMID35214131
PMCPMC8875545
OpenAlexW4213029815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.